Your browser doesn't support javascript.
loading
Multiparameter prediction of myeloid neoplasia risk.
Gu, Muxin; Kovilakam, Sruthi Cheloor; Dunn, William G; Marando, Ludovica; Barcena, Clea; Mohorianu, Irina; Smith, Alexandra; Kar, Siddhartha P; Fabre, Margarete A; Gerstung, Moritz; Cargo, Catherine A; Malcovati, Luca; Quiros, Pedro M; Vassiliou, George S.
Afiliação
  • Gu M; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
  • Kovilakam SC; Department of Haematology, University of Cambridge, Cambridge, UK.
  • Dunn WG; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
  • Marando L; Department of Haematology, University of Cambridge, Cambridge, UK.
  • Barcena C; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
  • Mohorianu I; Department of Haematology, University of Cambridge, Cambridge, UK.
  • Smith A; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
  • Kar SP; Department of Haematology, University of Cambridge, Cambridge, UK.
  • Fabre MA; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
  • Gerstung M; Department of Haematology, University of Cambridge, Cambridge, UK.
  • Cargo CA; Department of Biochemistry and Molecular Biology, Universidad de Oviedo, Oviedo, Spain.
  • Malcovati L; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
  • Quiros PM; Epidemiology and Cancer Statistics Group, University of York, York, UK.
  • Vassiliou GS; MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
Nat Genet ; 55(9): 1523-1530, 2023 09.
Article em En | MEDLINE | ID: mdl-37620601
ABSTRACT
The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0-15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters among individuals that later develop myeloid neoplasms (pre-MN) versus controls, finding that disease-specific changes are detectable years before diagnosis. By analyzing differences between 'pre-MN' and controls, we develop and validate Cox regression models quantifying the risk of progression to each myeloid neoplasm subtype. We construct 'MN-predict', a web application that generates time-dependent predictions with the input of basic blood tests and genetic data. Our study demonstrates that many individuals that develop myeloid neoplasms can be identified years in advance and provides a framework for disease-specific prognostication that will be of substantial use to researchers and physicians.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hematopoiese Clonal / Neoplasias Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hematopoiese Clonal / Neoplasias Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article